In this paper we present a novel drug delivery device that: 1. is able to release drug in a controllable way (one shot, multiple shots, continuous release); 2. has power requirements compatible with those of standard integrated circuits; 3. can be easily miniaturized. The actuation principle relies on the electrolysis of a waterbased solution that is kept separated from the drug by an elastic membrane. The pressure generated inside the chamber containing the electrolytic solution causes an outward deflection of the membrane that forces the drug to exit its storing chamber through an outlet orifice. The drug out-flow can be electronically controlled and different releasing modes can be achieved (one shot, multiple shots, continuous delivery). Voltages as low as 2V are able to activate the device, with extremely small currents ( 1mA). A first prototype has been fabricated and tested. Flowrate and pressure vs. time measurements have been performed, which confirm the suitability of the device for in-body applications.
Introduction
Modern diagnostic and therapeutic procedures address the quality of patients' care and are aimed at reducing pain and discomfort. This trend is enabled by and provides momentum to the development of microengineering and microfabrication techniques that allow the integration of complex functions into miniaturized devices that can be introduced into the human body to perform minimally invasive intervention. Microendoscopy is a major example. Research in microendoscopy is devoted to the miniaturization of devices and to the integration of microsystems into the tip of the endoscope in order to increase its functionalities 1 . A new trend recently emerged as a further evolution of microendoscopy: endoscopic wireless devices, usually referred to as endoscopic pills. In particular, three devices have been already developed by Given Imaging, Israel 2 , RF Lab, Japan and Intelli-gent Microsystem Center, Korea. Microprocessor controlled drug delivery is one of the foreseen tasks to be performed by endoscopic pills. Indeed, the integration on the same swallable device of one or more sensors and a microfluidic actuator for Drug Delivery (DD) allows specifically targeted therapeutic action, because the desired amount of drug can be released to the exact intervention site, located by the sensors. For example, no drug delivery may be performed if the expected physiological conditions are not encountered by the pill. A number of miniaturized mechatronic DD systems have been developed and proposed for in-body operation as components of clinical microsystems. A DD device may be classified following its operational principle into: 1) continuous delivery; 2) one shot delivery. The first kind includes the devices that exploit a micropump as active component 3 . In the latter type the opening of the outlet port is achieved through the destruction of a sealing membrane 4, 5 . Both types of devices have a number of positive and negative aspects. Independently from the working principle the actual implementation into in-body, autonomous, battery-operated systems imposes tight constraints to the maximum voltage and current intensity that must be supplied for actuation. This poses a major difficulty in the choice of a suitable actuation mechanism.
Methods
The DD system under development at CRIM Lab has to be inserted in a φ10 mm x 30 mm pill but its dimensions must be as small as possible to allow the mounting on the same pill of other devices and components (batteries, optics, microcontroller, etc.). The energy will be supplied by an on-board battery operating at 3V (Seiko, MS412F). The amount of drug to be released will be of the order of 1µl.
Traditionally, mechanical or electrokynetic micropumps are used to perform DD tasks. Nevertheless, the low voltage provided by the battery would require additional electronic circuit to increase the available voltage up to the requested values, usually above 100V. On the contrary, electrochemical actuation appears as a valid alternative 6 , since many exploitable electrochemical reactions occur at low voltage (below 3V). The dimensions of the DD capsule are shown in fig. 1 . The capsule comprises two chambers divided by an elastic membrane. The lower chamber contains the electrolytic solution (H 2 SO 4 , 0.1M) in contact with the two Al wires acting as electrodes. The upper chamber contains the drug to be delivered. The inert, elastic membrane assures the physical separation between the drug and the electrolytic solution. The electrolytic process is activated as soon as an appropriate voltage (typically less than 3V) is applied to the electrodes. H 2 is produced at the cathode following the reactions:
The rise of the pressure in the lower chamber is transmitted to the upper chamber by the membrane, so that the drug is forced to exit from the outlet hole.
When a constant voltage is applied, above a given threshold, the current flowing through the electrolytic cell is controlled by diffusive transport phenomena. In particular, the current is determined by the concentration of H + . Following Faraday's law, the production of H 2 will decrease in time as the pH of the solution increases. By assuming an ideal behavior of the evoluted gas, the following relation between pressure and time can be found:
where Q 0 (H + ) is the initial amount of H + , R is the universal constant of gases, T the absolute temperature, V 0 the interstitial volume, k the kynetic parameter associated with the decreasing of [H + ].
Experimental Results
The volume ejected at zero delivery head and the pressure at zero flowrate have been measured as a function of time ( fig. 2 ). The measurements have been performed by applying 3V to the electrodes. The flow rate has been measured using a precision balance (GR-200 by AND, with 0.1 mg resolution) while the pressure inside the lower chamber has been determined by measuring the force exerted by the membrane over a flat surface and dividing it by the area of the membrane. As expected (eq. 1) the response is not linear and a typical saturation behavior is shown, although it occurs after a long operation time (>200 s). The desired volume of 1µl is delivered after about 10 s. Drug can be delivered in different sites by repeated actuation of the DD capsule. In Figure 1 . Cross section of an electrochemical module for drug delivery (left) and axonometric view (right).
particular, for each µl of solution of H 2 SO 4 (0.1 M) in H 2 O, 0.1 µmol of H 2 can be released, corresponding to about 2.4µl of gas. Since the lower chamber contains about 15µl of electrolytic solution, the maximum drug volume that can be delivered is about 36µl.
A simple electrofluidic system has been fabricated in order to check the feasibility of sensors-based controllable release. The system comprises the following modules ( fig. 3 , left):
• DD capsule for the drug release (drugstor ); • a driver for the control of electrolytic process; • a sensing system; • a microcontroller module.
The driver provides a constant current source (up to 500 µA) because a controlled current allows a constant rate of drug release until saturation is reached. A miniaturized temperature sensor (LM35 by National Semiconductor, typical accuracy 0.2 o C) has been chosen to acquire information about the physiological conditions. The control strategy is implemented in a 8 bit microcontroller (PIC12F675 by Microchip). A simple threshold strategy has been implemented, as shown in fig. 4 . Nevertheless, different and more complex control strategies are implementable using the same microcontroller. The PIC12F675 performs also the A/D conversion and manages the driver activation and the power supply system. In particular, by switching off all other modules when inactive, only 7µA are required for operation in survey mode and small 3V batteries can be used. In fig.(3,  right) the overall dimensions of the device are shown. Further miniaturization can be easily achieved by using surface mounting discrete electronic components. 
Conclusions
In this paper a novel drug delivery device for intra-corporeal operation has been presented. The device has power requirements compatible to those of standard electronic circuits (3V, 1mA) and thus it requires only simple driving circuitry. Thanks to its small dimensions and reduced power requirements the device can be easily integrated into endoscopic wireless capsules. The performances of the device (maximum flow-rate and delivery head) have been experimentally validated.
